

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/658,116	09/08/2003	John P. Willis	BVTP-P02-004	9687
28120 FISH & NEAV	7590 05/02/2007 'E IP GROUP	•	EXAMINER	
ROPES & GRA	AY LLP		STIGELL, THEODORE J	
ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624			ART UNIT	PAPER NUMBER
			3763	
•				
			MAIL DATE	DELIVERY MODE
			05/02/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

			_/			
	Application No.	Applicant(s)	٠			
	10/658,116	WILLIS ET AL.				
Office Action Summary	Examiner	Art Unit				
	Theodore J. Stigell	3763				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 16(a). In no event, however, may a reply be tim rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 08 Se	eptember 2003.					
2a) This action is FINAL . 2b) ⊠ This	This action is FINAL . 2b)⊠ This action is non-final.					
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.				
Disposition of Claims	·					
4) Claim(s) 1 and 27-35 is/are pending in the appl	lication.					
4a) Of the above claim(s) is/are withdraw						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1 and 27-35</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9)⊠ The specification is objected to by the Examiner	r.					
10) The drawing(s) filed on is/are: a) acce		Examiner.				
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correcti	on is required if the drawing(s) is obj	jected to. See 37 CFR 1.121(d).				
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:	priority under 35 U.S.C. § 119(a))-(d) or (f).				
1.☐ Certified copies of the priority documents have been received.						
Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau	(PCT Rule 17.2(a)).	•				
* See the attached detailed Office action for a list of	of the certified copies not receive	ed.				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) 	Paper No(s)/Mail Da 5) Notice of Informal P					
Paper No(s)/Mail Date 10/17/2005,8/9/2004,1/12/2004.	6) Other:					

Art Unit: 3763

DETAILED ACTION

Specification

The disclosure is objected to because of the following informalities: Please update the Cross-Reference to Related Applications section.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 29-35 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. There is no disclosure of a "syringe adaptor housing".

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Art Unit: 3763

Claims 1 and 27-32 are rejected under 35 U.S.C. 102(e) as being anticipated by Weston (5,891,086). Weston discloses an injection device comprising a housing (111) having a proximal end and a distal end, the housing having a distal opening, a propellant (117) disposed within the housing and spaced from the distal end, a piston (104,102) having a first cavity disposed inside the housing between the distal end and the propellant, and a hollow sleeve (101) configured to mate with the piston, the sleeve having a second cavity, wherein a fluid travels between the interior of the housing to the exterior of the housing (through hole 116) without passing through the distal opening, wherein the hollow sleeve has a surface with at least one hole (114), and wherein the piston has one hole.

In regards to claims 29-32, Weston discloses an injection device comprising at least a first (51), second (18), third (2) and fourth housings (3), wherein the third housing has a syringe adaptor housing (26) having an outer vent sleeve, a movable piston (46) having an end and at least one relief hole (47), a fixed sleeve (44) adjacent the movable piston and having a groove with a hole, a drive piston (32) adjacent the end of the movable piston and having at least one groove, and a sealing device within the groove of the drive piston, wherein the first housing is demountably attached to the second housing, wherein the second housing is demountably attached to the third housing, and wherein the third housing is demountably attached to the fourth housing.

Claims 1 and 27-28 are rejected under 35 U.S.C. 102(e) as being anticipated by Weston et al. (6,620,135). Weston discloses an injection device comprising a housing (12) having a proximal end and a distal end, the housing having a distal opening, a

Art Unit: 3763

propellant (8) disposed within the housing and spaced from the distal end, a piston (3) having a first cavity disposed inside the housing between the distal end and the propellant, and a hollow sleeve (1) configured to mate with the piston, the sleeve having a second cavity, wherein a fluid travels between the interior of the housing to the exterior of the housing (through hole 13) without passing through the distal opening, wherein the hollow sleeve has a surface with at least one hole (14a), and wherein the piston has one hole.

Claims 1 and 27-28 are rejected under 35 U.S.C. 102(e) as being anticipated by Jacobsen et al. (6,045,534). Jacobsen discloses an injection device comprising a housing (12) having a proximal end and a distal end, the housing having a distal opening, a propellant (58) disposed within the housing and spaced from the distal end, a piston (16) having a first cavity disposed inside the housing between the distal end and the propellant, and a hollow sleeve (20) configured to mate with the piston, the sleeve having a second cavity, wherein a fluid travels between the interior of the housing to the exterior of the housing (through hole 63) without passing through the distal opening, wherein the hollow sleeve has a surface with at least one hole (51), and wherein the piston has one hole (hole through the piston cap).

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140

Application/Control Number: 10/658,116

Art Unit: 3763

F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1 and 27-35 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 6,616,627.

Although the conflicting claims are not identical, they are not patentably distinct from each other because the minor structural differences in the sets of claims do not pass the threshold of patentability.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Theodore J. Stigell whose telephone number is 571-272-8759. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/658,116

Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 6

Theodore J. Stigell

NICHOLAS D. LUCCHESI SUPERVISORY PAVENT EXAMINER TECHNOLOGY CENTER 3700